benzyl 7,9-dimethylspiro[5H-pyrrolo[1,2-a]quinoxaline-4,4'-piperidine]-1'-carboxylate | 1259377-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: benzyl 7,9-dimethylspiro[5H-pyrrolo[1,2-a]quinoxaline-4,4'-piperidine]-1'-carboxylate
• CAS: 1259377-65-5
• 化学式: C₂₅H₂₇N₃O₂
• 分子量: 401.508
• InChiKey: WBSHILNKCUDSDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS<br/>[FR] MULTIMÈRES DIHYDROPYRIMIDONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ÉLASTASE NEUTROPHILE HUMAINE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2006136857A1

  公开（公告）日：2006-12-28

  [EN] A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases.
  [FR] L'invention concerne un composé de formule M-L-M (I), où L est un liant et chaque M est indépendamment un groupe de formule (II), utile pour le traitement, par exemple, de maladies respiratoires.
• [EN] METHODS FOR USING PYRROLO-BENZO-1,4-DIAZINES AS SODIUM CHANNEL BLOCKERS<br/>[FR] PROCÉDÉS D'UTILISATION DE PYRROLO-BENZO-1,4-DIAZINES EN TANT QUE BLOQUEURS DE CANAUX SODIQUES
  申请人：SCHERING CORP

  公开号：WO2010151597A1

  公开（公告）日：2010-12-29

  Pyrrolo-benzo-1,4-diazine compounds represented by Formula I or II, or pharmaceutically acceptable salts thereof, are blockers of voltage-gated sodium channels. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, voltage-gated sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy or epilepsy conditions, irritable bowel syndrome, depression, anxiety, bipolar disorder, neurodegenerative disorders, psychiatric disorders, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, neuropathy and tinnitus, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.